Literature DB >> 19201994

Reversal of cardiac myocyte dysfunction as a unique mechanism of rescue by P2X4 receptors in cardiomyopathy.

Jian-Bing Shen1, Robin Shutt, Mariela Agosto, Achilles Pappano, Bruce T Liang.   

Abstract

Binary cardiac transgenic (Tg) overexpression of P2X(4) receptors (P2X(4)R) improved the survival of the cardiomyopathic calsequestrin (CSQ) mice. Here we studied the mechanism of rescue using binary P2X(4)R/CSQ Tg and CSQ Tg mice as models. Cellular and intact heart properties were determined by simultaneous sarcomere shortening (SS) and Ca(2+) transients in vitro and echocardiography in vivo. Similar to a delay in death, binary mice exhibited a slowed heart failure progression with a greater left ventricular (LV) fractional shortening (FS) and thickness and a concomitant lesser degree of LV dilatation in both systole and diastole at 8 or 12 wk. By 16 wk, binary hearts showed similarly depressed FS and thinned out LV and equal enlargement of LV as did 12-wk-old CSQ hearts. Binary cardiac myocytes showed higher peak basal cell shortening (CS) and SS as well as greater basal rates of shortening and relaxation than did the CSQ myocytes at either 8 or 12 wk. Similar data were obtained in comparing the Ca(2+) transient. At 16 wk, binary myocytes were like the 12-wk-old CSQ myocytes with equally depressed CS, SS, and Ca(2+) transient. CSQ myocytes were longer than myocytes from wild-type and binary mice at 12 wk of age. At 16 wk, the binary myocyte length increased to that of the 12-wk-old CSQ myocyte, parallel to LV dilatation. The data suggest a unique mechanism, which involves a reversal of cardiac myocyte dysfunction and a delay in heart failure progression. It represents an example of targeting the abnormal failing myocyte in treating heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201994      PMCID: PMC2670706          DOI: 10.1152/ajpheart.01316.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  25 in total

Review 1.  The effect of neurohormonal antagonists in reducing heart failure hospitalizations.

Authors:  Randall E Williams
Journal:  Curr Med Res Opin       Date:  2006-01       Impact factor: 2.580

Review 2.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

Review 3.  ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  Sharon Ann Hunt
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

4.  Comparison of contraction and calcium handling between right and left ventricular myocytes from adult mouse heart: a role for repolarization waveform.

Authors:  Richard P Kondo; Dorothy A Dederko; Christine Teutsch; Jacqueline Chrast; Daniele Catalucci; Kenneth R Chien; Wayne R Giles
Journal:  J Physiol       Date:  2005-12-15       Impact factor: 5.182

5.  Lack of effect of McN-A-343 on membrane current and contraction in guinea pig ventricular myocytes.

Authors:  J B Shen; B Jiang; A J Pappano
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

6.  Extracellular ATP-stimulated current in wild-type and P2X4 receptor transgenic mouse ventricular myocytes: implications for a cardiac physiologic role of P2X4 receptors.

Authors:  Jian-Bing Shen; Achilles J Pappano; Bruce T Liang
Journal:  FASEB J       Date:  2006-02       Impact factor: 5.191

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  A beneficial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy.

Authors:  Alexander Yang; Dimitry Sonin; Larry Jones; William H Barry; Bruce T Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-05-06       Impact factor: 4.733

9.  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

Authors: 
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  11 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

2.  The effects of aerobic interval training on the left ventricular morphology and function of VLCAD-deficient mice.

Authors:  Charles E Riggs; Marcos A Michaelides; Koulla M Parpa; Nancy J Smith-Blair
Journal:  Eur J Appl Physiol       Date:  2010-07-17       Impact factor: 3.078

3.  Effects of ATP administration on isolated swine hearts: Implications for ex vivo perfusion and cardiac transplantation.

Authors:  Maria S Seewald; Erik N Gaasedelen; Tinen L Iles; Lars M Mattison; Alexander R Mattson; Megan M Schmidt; Ruediger C Braun-Dullaeus; Paul A Iaizzo
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-27

4.  Cardiac P2X purinergic receptors as a new pathway for increasing Na⁺ entry in cardiac myocytes.

Authors:  Jian-Bing Shen; Ronghua Yang; Achilles Pappano; Bruce T Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-19       Impact factor: 4.733

5.  Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptors.

Authors:  Si-Yuan Zhou; Mohammed Mamdani; Khaled Qanud; Jian-Bing Shen; Achilles J Pappano; T Santhosh Kumar; Kenneth A Jacobson; Thomas Hintze; Fabio A Recchia; Bruce T Liang
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

6.  The therapeutic effect of 2-cyclohexylthio-AMP in heart failure.

Authors:  Siyuan Zhou; Tiehong Yang; Kenneth A Jacobson; Bruce T Liang
Journal:  J Cardiovasc Pharmacol       Date:  2013-06       Impact factor: 3.105

7.  Novel protective role of endogenous cardiac myocyte P2X4 receptors in heart failure.

Authors:  Tiehong Yang; Jian-bing Shen; Ronghua Yang; John Redden; Kimberly Dodge-Kafka; James Grady; Kenneth A Jacobson; Bruce T Liang
Journal:  Circ Heart Fail       Date:  2014-03-12       Impact factor: 8.790

Review 8.  P2X4 receptor-eNOS signaling pathway in cardiac myocytes as a novel protective mechanism in heart failure.

Authors:  Ronghua Yang; Dardan Beqiri; Jian-Bing Shen; John M Redden; Kimberly Dodge-Kafka; Kenneth A Jacobson; Bruce T Liang
Journal:  Comput Struct Biotechnol J       Date:  2014-11-07       Impact factor: 7.271

9.  The Ionotropic P2X4 Receptor has Unique Properties in the Heart by Mediating the Negative Chronotropic Effect of ATP While Increasing the Ventricular Inotropy.

Authors:  Bruno Bragança; Sílvia Nogueira-Marques; Fátima Ferreirinha; Ana Patrícia Fontes-Sousa; Paulo Correia-de-Sá
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

10.  CD13 is essential for inflammatory trafficking and infarct healing following permanent coronary artery occlusion in mice.

Authors:  Flavia E Pereira; Chunxia Cronin; Mallika Ghosh; Si-Yuan Zhou; Mariela Agosto; Jaganathan Subramani; Ruibo Wang; Jian-Bing Shen; Wolfgang Schacke; Brannen Liang; Tie Hong Yang; Beata McAulliffe; Bruce T Liang; Linda H Shapiro
Journal:  Cardiovasc Res       Date:  2013-06-12       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.